Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men

Journal of Urology

Volumn 172, Issue 3, 2004, Pages 920-922

  Kaufman, Joel M ^a   Graydon, R James ^b  

^a Aurora Urology   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Hypogonadism; Prostatic neoplasms; Testosterone

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; BIOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG FORMULATION; DRUG PATCH; GEL; GLEASON SCORE; HUMAN; HYPOGONADISM; MALE; MEDLINE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SCORING SYSTEM; SUSTAINED RELEASE PREPARATION; TESTOSTERONE BLOOD LEVEL;

EID: 4143066958     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000136269.10161.32     Document Type: Article

References (17)

1. Han, M., Partin, A. W., Zahurak, M., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol, 169: 517, 2003
2. Arver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W. et al: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol, 47: 727, 1997
3. Cunningham, G. R., Hirshkowitz, M., Korenman, S. G. and Karacan, I.: Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab, 70: 792, 1990
4. Hajjar, R. R., Kaiser, F. E. and Morley, J. E.: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab, 82: 3793, 1997
5. Davidson, J. M., Camargo, C. A. and Smith, E. R.: Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab, 48: 955, 1979
6. World Health Organization: 3rd International Consensus Consultation on Prostate Cancer, Paris, France, 2002
7. Fowler, J. E., Jr. and Whitmore, W. F., Jr.: Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer, 49: 1373, 1982
8. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Carol Kosary, M. A., Cerhan, J., Correa, R. et al: Prostate Cancer Trends 1973-1995, SEER Program. Bethesda: National Institutes of Health, National Cancer Institute, 1999
9. Eaton, N. E., Reeves, G. K., Appleby, P. N. and Key, T. J.: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer, 80: 930, 1999
10. Slater, S. and Oliver, R. T.: Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging, 17: 431, 2000
11. Gerstenbluth, R. E., Maniam, P. N., Corty, E. W. and Seftel, A. D.: Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl, 23: 922, 2002
12. Ludwig, G.: PADAM from the urologic viewpoint. Urologe A, 39: 407, 2000
13. Morales, A.: Androgen replacement therapy and prostate safety. Eur Urol, 41: 113, 2002
14. Wang, C., Swedloff, R. S., Iranmanesh, A., Dobs, A., Snyder, P. J., Cunningham, G. et al: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab, 85: 2839, 2000
15. Jackson, J. A., Waxman, J. and Spiekerman, A. M.: Prostatic complications of testosterone replacement therapy. Arch Intern Med, 149: 2365, 1989
16. Loughlin, K. R. and Richie, J. P.: Prostate cancer after exogenous testosterone treatment for impotence. J Urol, 157: 1845, 1997
17. Curran, M. J. and Bihrle, W., 3rd: Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology, 53: 423, 1999